This is a follow up to my first article on The James, as we pick it up with a very brief Q&A with Eileen Scahill of The James. This will be the 2nd in an ongoing series I’ll do on The James.
One side note before Eileen takes the stage. Cancer is a horrendous disease, or more accurately a horrendous family of diseases and as stated in the earlier article, The James has established itself as a leading research and treatment center. For one example, if you get multiple myeloma (and I don’t recommend iyou do), the staff at The James treats upwards to 90% of the reported cases in Ohio, or slightly more than 600 patients per year, as well as out of state patients. Providing a critical service to state residents, as well as the general community at large, is certainly an example of the OSUCCC-James fulfilling The Ohio State University Vision.
I’d asked Eileen acouple of questions, and she was gracious enough to provide some informative detail of the OSUCCC-James.
The James is one of only seven centers in the country funded by the National Cancer Institute to conduct both phase I and phase II clinical trials for new anti-cancer drugs. The resulting benefit to patients is that they have access to some of the most advanced cancer treatments and clinical trials offered anywhere in the world. When you participate in a clinical trial, you receive the same excellent cancer care you would normally receive. In addition, you have access to new treatments that are only available through the clinical trial. A clinical trial may involve the collection of cancer tissue and fluids, while others test new drugs or combinations of drugs and still others evaluate new approaches to preventing cancer. Patients interested in learning more about clinical trials are encouraged to ask their doctor for more information.
In the realm of cancer research, every discovery is significant for its potential use against a dreaded disease. Hence the rising global emphasis on “translational research,” which the National Cancer Institute (NCI) defines as transforming scientific discoveries from laboratory, clinical and population studies into medical applications for reducing cancer incidence, morbidity or mortality.
These discoveries typically begin in the laboratory with basic research in which scientists study disease at the molecular or cellular level and make observations that can be translated to patient care via clinical trials that test the safety and effectiveness of new medications in cancer patients with few or no other treatment options. But translational research is really circular, because clinicians then make novel observations about how the new medications work in their patients and relay this knowledge back to the laboratory, often stimulating further basic science investigations.
With our strong focus on collaboration between basic and clinical researchers, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC-James) provides an ideal atmosphere for translational research. Collaboration here is evident in everything from our standing as one of the most comprehensive health sciences institutions in the United States, to our emphasis on open labs and shared resources that promote working across disciplines and efficient use of research funding, to our creation of biomedical informatics data banks that help us share our discoveries across the University and around the world.
OSUCCC-James researchers are conducting hundreds of clinical trials in virtually every form of cancer, with particular focus on hematologic malignancies, including leukemias, lymphomas and multiple myeloma; along with solid tumor including breast, lung, prostate cancers. Other clinical trials are being conducted for colorectal cancer, ovarian cancer, uterine cancer; liver cancer, melanoma, stomach and thyroid cancers, among others.
We attract patients primarily from central Ohio, but also have patients who seek treatment here from elsewhere in Ohio and nationwide.
Stats for Fiscal Year 2011 for The James:
Hospital Admissions – 10,368
Outpatient Visits – 239,155
Clinic Visits – 107,452
Our research portfolio is in excess of $110 million, representing roughly one-fifth of Ohio State’s entire research portfolio.